Prevalence, causes, medical interventions, and mortality outcome of acute gastrointestinal bleeding among COVID-19 inpatients

• Published in: Current medical research and opinion 2023-05, Vol.39 (5), p.731-737
• Main Authors: Luu, Mai N., Dang, Thinh P., Vo, Minh-Cong H., Quach, Duc T.
• Format: Article
• Language: English
• Subjects: COVID-19; COVID-19 - complications; Endoscopy, Gastrointestinal - adverse effects; Gastrointestinal hemorrhage; Gastrointestinal Hemorrhage - epidemiology; Gastrointestinal Hemorrhage - therapy; Humans; Inpatients; kidney diseases; liver diseases; Male; peptic ulcer; Peptic Ulcer - complications; Prevalence; Retrospective Studies; Risk Factors; Vietnamese
• ISSN: 0300-7995; 1473-4877
• DOI: 10.1080/03007995.2023.2201097

Since there is not enough information of sudden digestive tract bleeding among Asian populations with COVID-19, this study aimed to measure the proportion of existing cases, causes, medical treatments and deaths of sudden digestive tract bleeding in COVID-19 patients who were hospitalized during the Delta-variant pandemic in Vietnam. We collected medical records of 1567 COVID-19 patients from a specialty hospital in Vietnam from July to October 2021. Sudden digestive tract bleeding was present in 3.6% of COVID-19 inpatients. The risk of sudden digestive tract bleeding was higher in COVID-19 patients who were old, male, or had long-term liver or kidney disease. The most common cause of sudden digestive tract bleeding among COVID-19 inpatients were stomach ulcers. In addition, COVID-19 inpatients with sudden digestive tract bleeding had a higher risk of death, but a large proportion of deaths were not bleeding-related. This study aimed to evaluate the prevalence, causes, medical interventions, and mortality outcome of acute gastrointestinal bleeding (AGIB) among COVID-19 patients hospitalized during the delta pandemic in Vietnam. The medical records of COVID-19 patients hospitalized in a tertiary hospital in Vietnam from July to October 2021 were retrospectively collected. Data regarding age, sex, comorbidities, COVID-19 severity, onset time of AGIB, therapeutic interventions for AGIB, and mortality outcome were analyzed. Of 1567 COVID-19 inpatients, 56 (3.6%) had AGIB. The independent risk factors for AGIB in COVID-19 inpatients included age (OR = 1.03, 95% CI: 1.01-1.04, p = .003), male sex (OR = 1.86, 95% CI: 1.06-3.26, p = .03), chronic liver disease (OR = 6.21, 95% CI: 2.97-13.00, p